Tracer library / [177Lu]Lu-AKIR001

[177Lu]Lu-AKIR001

Also written as [Lu-177]Lu-AKIR001

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 2

Pan-cancer / multiple tumour types Other radioligand therapy

What it is

Compound class: CD44v6-targeted antibody conjugated with DOTA chelator, radiolabeled with Lu-177
Target / mechanism: CD44v6-targeted antibody radiotherapeutic PMID 41198237
Clinical application: CD44v6-positive solid cancers, phase 1 clinical trial PMID 41198237
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	—	AKIR001 antibody conjugated with…AKIR001 antibody conjugated with p-SCN-Bn-DOTA	42707719 2026 Theranostics [161Tb]TbCl3 was mixed with AKIR001 (10.4 µg/µl in a phosphate buffer with 0.04% polysorbate 80 (PS80), pH 6.5).
Manual synthesis	—	—	≥99%	—	AKIR001 antibody SciLifeLab, Absolute Antibody, or Genscript Probio	41198237 2026 J Nucl Med 177Lu-labeling involved incubating 50–400 µg of antibody with 15–130 MBq of 177Lu at 37 °C (≥99% yield) - ≥99% yield

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: SciLifeLab, Absolute Antibody
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-AKIR001, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42707719: 'AKIR001 antibody conjugated with p-SCN-Bn-DOTA'. Stage set/updated at stage 23 from PMID 41198237: 'A phase 1 clinical trial of [177Lu]Lu-AKIR001for CD44v6-positive solid cancers (NCT06639191) is currently recruiting patients.'. | Stage 30 (2026-09-18): Stage was 'phase 1 clinical trial'; normalised to 'Clinical research', original wording kept here.